2021 Speakers Included:

Andrew Byrnes

Chief, Gene Transfer and Immunogenicity Branch

US FDA

Klaudia Kuranda

Immunology Lead

Spark Therapeutics

David Markusic

Research Professor

IUPUI

Cathryn Clary

Acting Chief Medical Officer

Bridge Bio

Federico Mingozzi

Chief Scientific Officer

Spark Therapeutics

Susan Ward

Founder & Executive Director

cTAP - Duchenne

John Kamerud

Bioanalytical Lead

Pfizer

Boris Gorovitz

Vice President, In vitro Pharmacology, Biomarker Discovery & Bioanalysis at Development Sciences

Sana Biotechnology

Roberto Calcedo

Vice President, Preclinical and Immunology

Affinia Therapeutics

MiJeong MJ Kim (MJ)

Associate Director of Immunology

Homology Medicines

Maria Lobikin

Associate Director, CMC Regulatory Affairs

Homology Medicines

Kei Kishimoto

Chief Scientific Officer

Selecta Bioscience

Roland Herzog

Riley Children’s Foundation Professor of Immunology

Indiana University

Pierre Burguiere

Independent Consultant

Genevieve Laforet

Vice President, Clinical Development

Aspa Therapeutics

Genine Winslow

Chief Scientific Officer

Chameleon Bioscience

Jose Trevejo

CDO

Rocket Pharmaceuticals

Liching Cao

Director, Bioanalytical Operations

Sangamo Therapeutics

Vibha Jawa

Executive Director

Bristol Myers Squibb

Guangping Gao

Professor & Director

UMass Medical School

Zuben Sauna

Principal Investigator

US FDA

Susan Ward

Founder & Executive Director

cTAP - Duchenne

Helene Haegel

Principal Scientist Immunosafety

Roche

Ravi Samavedam

President & COO

Azzur Group

Mark Milton

Opthalmology Area Head

Novartis

Giuseppe Gonzitti

Group Leader

Genethon

Stephen DeWall

Biopharmaceutical Immunogenicity Leader

Spark Therapeutics

Travis Harrison, PhD

Vice President

Bioassay Solutions